Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation-Reference-Cited by-同舟云学术

Recurrent DDX41 mutation in very late relapse after allogeneic stem cell transplantation

Published:2024-01-18 Issue:3 Volume:38 Page:667-670
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kambara Yasuhiro^ORCID,Sadato Daichi,Toya Takashi^ORCID,Honda Akira,Kato Seiko,Hirama Chizuko,Haraguchi Kyoko,Shimizu Hiroaki,Najima Yuho^ORCID,Kobayashi Takeshi,Okuyama Yoshiki,Harada Hironori^ORCID,Takahashi Satoshi^ORCID,Kurokawa Mineo,Harada Yuka,Doki Noriko^ORCID

Funder

This research was supported in part by The Japanese Society of Hematology Research Grant and Clinical Research Fund of Tokyo Metropolitan Government.

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41375-024-02152-7.pdf

Reference15 articles.

1. Watts JM, Wang XV, Swords RT, Paietta E, Douer D, Lugar SM, et al. Very late relapse of AML after allogeneic hematopoietic cell transplantation is often extramedullary. Bone Marrow Transpl. 2016;51:1013–5.

2. Sadato D, Hirama C, Kaiho-Soma A, Yamaguchi A, Kogure H, Takakuwa S, et al. Archival bone marrow smears are useful in targeted next-generation sequencing for diagnosing myeloid neoplasms. PLoS One. 2021;16:e0255257.

3. Adachi H, Sadato D, Toya T, Hirama C, Haraguchi K, Mukae J, et al. Donor-derived gene mutations in sex chromosome loss after stem cell transplantation. Br J Haematol. 2021;195:e142–6.

4. Makishima H, Saiki R, Nannya Y, Korotev S, Gurnari C, Takeda J, et al. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023;141:534–49.

5. Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, et al. Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants. Am J Hematol. 2023;98:1780–90.